Core Insights - Meituan has launched the weight loss drug Masitide injection (brand name: Xin'ermei) on its self-operated pharmacy platform, marking another exclusive online debut of GLP-1 drugs following oral versions of Semaglutide and Tirzepatide [1][3] - Masitide is the world's first approved GCG/GLP-1 dual receptor agonist for weight management, showing a maximum weight loss of 21% over 20 weeks in clinical trials [3] - The global GLP-1 drug market is projected to exceed $60 billion by 2025, with China's market expected to reach $4.5 billion and an annual growth rate of over 28% [3] Company Developments - Meituan has upgraded its transportation equipment to ensure the quality of GLP-1 drugs during delivery, utilizing specialized temperature-controlled transport boxes [1] - The self-operated pharmacy has introduced a "no weight loss, no pay" service and online consultations with top-tier hospital doctors to enhance user experience in weight management [3] Product Features - Masitide's injection device offers improved convenience and safety, featuring a needle-free design and innovative X-section technology for painless injections [3] - The dual-target mechanism of Masitide not only enhances weight loss effects but also significantly reduces visceral fat by up to 80% and improves metabolic issues such as hypertension and hyperglycemia [3]

Group 1 - The newly approved weight loss drug, Marsutide injection, has been launched on Meituan's self-operated pharmacy platform [1] - Alongside the previously launched oral versions, Semaglutide and Tirzepatide, these three drugs will compete on the Meituan platform [1]